Physician profile
Robert S Pranger
NPI 1972582856
$4,321.82
in general payments reported to CMS, 2019-2025
29 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $526 · 2021: $734 · 2022: $1,062 · 2023: $671 · 2024: $553 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,675.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,110.00 | 2021-2025 | |
| Pfizer INC. | $540.85 | 2021-2025 | |
| Lilly USA, LLC | $442.18 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $370.62 | 2020-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $244.98 | 2019-2022 | |
| Allergan, INC. | $192.27 | 2019-2020 | |
| Novo Nordisk INC | $177.11 | 2020-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $166.04 | 2020-2023 | Breztri |
| Biohaven Pharmaceutical Holding Company LTD. | $165.55 | 2022 | |
| Amgen INC. | $150.02 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.53 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $80.77 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $80.41 | 2024 | Voquezna |
| Sanofi Pasteur INC. | $69.60 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $65.22 | 2023-2024 | Quviviq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $49.24 | 2023-2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $48.72 | 2023-2025 | Seglentis, Zoryve |
| Xeris Pharmaceuticals, INC. | $46.38 | 2024-2025 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $33.76 | 2020-2021 | |
| Harmony Biosciences LLC | $31.57 | 2024-2025 | |
| Almatica Pharma LLC | $28.58 | 2022 | |
| Medline Industries LP | $27.20 | 2025 | |
| Abbott Laboratories | $16.67 | 2023 | Freestyle Libre 2 |
| Vertex Pharmaceuticals Incorporated | $16.33 | 2025 | |
| Kaleo, INC. | $14.78 | 2019 | |
| Vanda Pharmaceuticals INC. | $14.07 | 2021 | |
| Glaxosmithkline, LLC. | $13.81 | 2021 | |
| Medicure Pharma INC. | $12.34 | 2019 | |
| Organon LLC | $10.22 | 2023 | Jada System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Pranger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.